Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Lord Abbett

Lord Abbett Health Care Fund Class I (LHCIX)

Ticker LHCIX · Since 2019-07-31 · · Holdings as of Jul 31, 2026

Expense ratio
0.78%$78/yr per $10k
5-yr return
+4.6%annualized
1-yr return
+17.9%as of Dec 2025
Net assets
$8.6Mall share classes
Holdings
61

Bottom line

Is LHCIX a good fund? The bottom line

LHCIX is the Class I share class of Lord Abbett Health Care Fund, an actively managed health care sector mutual fund from Lord Abbett.

It charges 0.78% — about $78 a year on every $10,000 invested, cheaper than 64% of health care sector funds we track.

It returned +17.9% over one year, +4.6% a year over five years (as of Dec 31, 2025, per its prospectus).

With $8.6 million in net assets and 61 holdings, its largest position is Eli Lilly & Co (10.4%) and the top 10 make up 42.9% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Small fund ($8.6 million) — small funds are likelier to close

Updated Nov 19, 2026

What LHCIX invests in

The Funds investment objective is to seek long-term capital appreciation.

Under normal conditions, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity and equity-related securities of health care-related companies. The Fund considers health care-related companies to be those companies that operate in, or are related to, the major subsectors of the health care sector, including pharmaceuticals, biotechnology, health care technology, life sciences tools and services, health care equipment and supplies, and health care providers and services. The Funds allocation among these areas will vary based on the portfolio management teams outlook for the particular subsector and the health care sector overall. The Fund normally invests at least 25% of its total assets, in the aggregate, in the following industry groups: health care equipment and services and pharmaceuticals, biotechnology, and life…

From the fund's prospectus (filed Feb 25, 2026).

LHCIX performance

Average annual total returns
1 yr5 yr10 yr
LHCIX+17.9%+4.6%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full LHCIX performance history →

What LHCIX costs

On a $10,000 investment, LHCIX's 0.78% expense ratio costs about $78 a year. The prospectus estimates $3,362 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full LHCIX fee table →

LHCIX top 10 holdings

#Holding% of fund
1Eli Lilly & Co10.40%
2UnitedHealth Group Inc5.39%
3Johnson & Johnson4.96%
4Novartis AG4.19%
5Natera Inc3.60%
6Gilead Sciences Inc3.53%
7CVS Health Corp3.33%
8Guardant Health Inc2.61%
9Galderma Group AG2.60%
10Thermo Fisher Scientific Inc2.31%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 42.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to LHCIX

More funds like LHCIX →

LHCIX FAQ

What is the expense ratio of LHCIX?
LHCIX's expense ratio is 0.78%, which works out to about $78 a year for every $10,000 invested. The prospectus estimates total costs of $3,362 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LHCIX a good investment?
It depends on your goals, but the data points to: no front-end sales load; small fund ($8.6 million) — small funds are likelier to close. This is general information, not personalized advice.
What does LHCIX hold?
LHCIX's largest holdings are Eli Lilly & Co (10.4%), UnitedHealth Group Inc (5.4%), Johnson & Johnson (5.0%), Novartis AG (4.2%), Natera Inc (3.6%). It holds 61 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is LHCIX's 5-year return?
LHCIX returned +4.6% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does LHCIX have a sales load?
No. LHCIX has no front-end sales charge.
Who manages LHCIX?
LHCIX is offered by Lord Abbett through Lord Abbett Securities Trust.